Fig. 1From: Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumabImprovement in patients using etanercept, adalimumab or tocilizumab according to the Pediatric American College of Rheumatology (PedACR)30/50/70 and 90 criteriaBack to article page